Biofrontera Inc. Stock-Based Compensation
Biofrontera Inc. (BFRI) reported Stock-Based Compensation of $605.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- Biofrontera Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $263.00K, a 40.64% increase year-over-year.
- Biofrontera Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $342.00K, a 43.10% increase year-over-year.
- Biofrontera Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $289.00K, a 3.34% decline year-over-year.
- Biofrontera Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $236.00K, a 18.06% decline year-over-year.
- Biofrontera Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $951.00K, a 6.67% decline from fiscal 2024.
- Biofrontera Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $1.02M, a 2.49% decline from fiscal 2023.
- Biofrontera Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $1.04M, a 43.57% decline from fiscal 2022.
- Biofrontera Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $1.85M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $263.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $605.00K 10-Q · filed 2026-08-13 | $894.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.13M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $342.00K 10-Q · filed 2026-05-14 | $631.00K derived: sum of 2 quarters · filed 2026-05-14 | $867.00K derived: sum of 3 quarters · filed 2026-05-14 | $1.05M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $289.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $525.00K derived: sum of 2 quarters · filed 2026-03-19 | $712.00K derived: sum of 3 quarters · filed 2026-08-13 | $951.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $236.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $423.00K derived: sum of 2 quarters · filed 2026-08-13 | $662.00K 10-Q · filed 2025-11-12 | $961.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $187.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $426.00K 10-Q · filed 2026-08-13 | $725.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.01M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $239.00K 10-Q · filed 2026-05-14 | $538.00K derived: sum of 2 quarters · filed 2026-05-14 | $826.00K derived: sum of 3 quarters · filed 2026-05-14 | $1.03M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $299.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $587.00K derived: sum of 2 quarters · filed 2026-03-19 | $791.00K derived: sum of 3 quarters · filed 2026-03-19 | $1.02M 10-K · filed 2026-03-19 |
| 2024-09-30 | $288.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $492.00K derived: sum of 2 quarters · filed 2025-11-12 | $720.00K 10-Q · filed 2025-11-12 | $948.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $204.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $432.00K 10-Q · filed 2025-08-13 | $660.00K derived: sum of 3 quarters · filed 2025-08-13 | $867.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $228.00K 10-Q · filed 2025-05-15 | $456.00K derived: sum of 2 quarters · filed 2025-05-15 | $663.00K derived: sum of 3 quarters · filed 2025-05-15 | $922.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $228.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $435.00K derived: sum of 2 quarters · filed 2025-03-20 | $694.00K derived: sum of 3 quarters · filed 2025-03-20 | $1.04M 10-K · filed 2025-03-20 |
| 2023-09-30 | $207.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $466.00K derived: sum of 2 quarters · filed 2024-11-14 | $817.00K 10-Q · filed 2024-11-14 | $1.20M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $259.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $610.00K 10-Q · filed 2024-08-14 | $993.00K derived: sum of 3 quarters · filed 2024-08-14 | $1.39M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $351.00K 10-Q · filed 2024-05-15 | $734.00K derived: sum of 2 quarters · filed 2024-05-15 | $1.14M derived: sum of 3 quarters · filed 2024-05-15 | $1.69M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $383.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $784.00K derived: sum of 2 quarters · filed 2024-03-15 | $1.33M derived: sum of 3 quarters · filed 2024-03-15 | $1.85M 10-K · filed 2024-03-15 |
| 2022-09-30 | $401.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $952.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.47M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $551.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $1.07M 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | $517.00K 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $129.00K 8-K · filed 2023-10-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |